Was Beethoven’s death-the result of medical malpractice? This week the OJC team tackle this crucial question plus the microbiome, trial design bias, five year outcomes for metastatic non-small-cell lung cancer and much more.
The Oncology Podcast, brought to you by Oncology News Australia, is proud to present Episode 33 in our series The Oncology Journal Club.
Was Beethoven’s death the result of medical malpractice? This week the OJC team tackle this crucial question plus the microbiome, trial design bias, five year outcomes for metastatic non-small-cell lung cancer and much more…
Hans Prenen gets us started by talking us through the connection between the gut microbiome and immune checkpoint inhibitors and Eva Segelov has a mega paper this week… She tackles our friend Bishal Gyawali’s paper addressing biases in study design that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale. Fascinating stuff!
Then Craig Underhill gives us his thoughts on Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer.
Today’s Quick Bites are as diverse as ever covering highlights from the AACR ASM, Fecal transplants for patients with cachexia, the TAPUR trial, Controversies in Thoracic Oncology, the costs of fear of cancer recurrence and much more.
And it wouldn’t be the OJC without something quirky too – this week won’t disappoint you as we have not one but two amazing papers of the week! Including one that asks if Beethoven’s death was a result of medical malpractice? Listen to find out more.
About The Oncology Journal Club:
We have taken an old concept and updated it with a new format. In each episode a team of expert contributors will review topical journal papers and interview special guests who are leaders in their fields to help keep you informed of the latest developments on the go.
With The Oncology Podcast – and The Oncology Journal Club in particular – we are aiming to deliver oncology news differently,” Rachael Babin, Editor-in-Chief, Oncology News.
The Oncology Journal Club is hosted by Professor Eva Segelov, from Monash University. Eva is joined by Dr Craig Underhill from Albury-Wodonga and Professor Hans Prenen from Antwerp, Belgium. We hope you enjoy listening and find this a valuable and entertaining resource.
This Week’s Papers:
- Evidence mounts for connection between gut microbiome and immune checkpoint inhibitors. AACR News. Published on April 15, 2021. Access online here.
- Gyawali B, et al. Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring. ESMO Open. 2021 Apr 19;6(3):100117. doi: 10.1016/j.esmoop.2021.100117. Epub ahead of print. Access online here.
- Reck M, et al. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50. J Clin Oncol. 2021 Apr 19:JCO2100174. doi: 10.1200/JCO.21.00174. Epub ahead of print. Access online here.
This Week’s Quick Bites:
- de Clercq NC, et al. Fecal Microbiota Transplantation from Overweight or Obese Donors in Cachectic Patients with Advanced Gastroesophageal Cancer: A Randomized, Double-blind, Placebo-controlled, Phase II Study. Clin Cancer Res. 2021 Apr 21:clincanres.4918.2020. doi: 10.1158/1078-0432.CCR-20-4918. Epub ahead of print. Access online here.
- Alva AS, et al. Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. J Clin Oncol. 2021 Apr 12:JCO2002923. doi: 10.1200/JCO.20.02923. Access online here.
- Adjei, A A. Controversies in Thoracic Oncology. Journal of Thoracic Oncology, Volume 16, Issue 3, 366 – 367. Access online here.
- Remon, J, et al. Osimertinib Should be the Standard of Care for the Adjuvant Therapy of Stage IB to IIIA EGFR-Mutant NSCLC. Journal of Thoracic Oncology, Volume 16, Issue 3, 368 – 370. Access online here.
- Uprety, D. Osimertinib Should Not Yet Be Considered the Standard of Care for EGFR-Mutant NSCLC in the Adjuvant Setting. Journal of Thoracic Oncology, Volume 16, Issue 3, 371 – 374. Access online here.
- Sechi E, Zekeridou A. Neurologic Complications of Immune Checkpoint Inhibitors in Thoracic Malignancies. J Thorac Oncol. 2021 Mar;16(3):381-394. doi: 10.1016/j.jtho.2020.11.005. Epub 2020 Nov 11. Access online here.
- Williams, J.T.W., Pearce, A. and Smith, A.’. (2021), A systematic review of fear of cancer recurrence related healthcare use and intervention cost‐effectiveness. Psycho‐Oncology. Access online here.
- Bardia, A. et al. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med 2021; 384:1529-1541. Access online here.
- Gillessen, S., et al. Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. Journal of Clinical Oncology. Published online April 06, 2021. Access online here.
- Mulcahy, N. Five Clinical Highlights From AACR Annual Meeting (Part 1). Medscape. Access online here.
Amazing Papers of the Week:
- Morgan, AC., et al. The unequal impact of parenthood in academia. Science Advances. 24 Feb 2021: Vol. 7, no. 9, eabd1996 Access online here.
- Reiter C, Prohaska T. Beethoven’s death-the result of medical malpractice? Wien Med Wochenschr. 2021 Mar 25. English. doi: 10.1007/s10354-021-00833-x. Epub ahead of print. Access online here.
Other Episodes Mentioned:
This Week’s Team:
Professor Eva Segelov
Professor Eva Segelov is a Medical Oncologist and is Director of Oncology at Monash University and Monash Health, Melbourne, Victoria, previously Senior Medical Oncologist at St Vincent’s Hospital, St Vincent’s Private Hospital and St Vincent’s Clinic and Associate Professor of Medicine, University of New South Wales.
Eva has an interest in academic clinical trials in GI and breast cancer and has been a member of the AGITG since 2003. She has clinical trials expertise, links with national and international trials groups, and extensive experience with adult medical education.
You can find Eva on Twitter here: @profevasegelov
Dr Craig Underhill
Dr Craig Underhill completed his Bachelor of Medicine and Surgery in 1987 at Melbourne University. He completed medical oncology training in Melbourne and worked as the Senior Clinical Research Registrar at Guy’s Hospital, London.
In 1998 arrived in Albury-Wodonga and established a medical oncology practice and clinical trials unit which has developed expertise and infrastructure to ensure the initiation of high quality trials. The research Unit lead by Dr Underhill has twice been awarded NSW Premier’s Award for Innovation in Cancer Clinical Trials, the inaugural award in 2009 and then again in 2012.
Dr Underhill chaired a working party that was instrumental in securing $65 million in federal funding for The Albury Wodonga Regional Cancer Centre which opened in September 2016.
Dr Underhill is the VCCC Regional Oncology Lead and advocates for the increased access to clinical trials for regional Victorians and leads the VCCC teletrials program.
You can find Craig on Twitter here: @CraigUnderhill
Professor Hans Prenen
Professor Hans Prenen is a medical oncologist and head of the phase 1 – early clinical trials unit at the Antwerp University Hospital in Belgium. He is a member of several scientific organisations, published many scientific oncology papers in prestigious journals and is regularly invited for lectures at national and international meetings. His interests are clinical trials and translational research with a focus on digestive oncology.
You can find Hans on Twitter here: @HPrenen
Rachael Babin is Editor-in-Chief of The Oncology Newsletter, Publisher of Oncology News Host of The Oncology Podcast and Producer of The Oncology Journal Club. For regular oncology updates for healthcare professionals, please subscribe to The Oncology Newsletter.
With thanks to Eva Segelov, Craig Underhill, Hans Prenen and Graham Knowles.
Connect with us on Twitter @OncologyNewsAus #OJC